DHR Danaher (DHR) Insider Trading, Ownership & Congress Trades
Industrials · Industrial instruments for measurement, display, and control · CIK 0000313616
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
847
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $711.2K priced
What the filings say about DHR
Insiders, 180 days
-$13.0M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 2 sold
Latest: sale, 2026-09-02
Planned sales (Form 144), 90 days
$12.7M
1 notice
Danaher insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, DANAHER CORP /DE/ insiders sold a net $13.0M of stock across 126 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 31, 2024.
- The trade is 24.1% of the 46,948 shares held after it.
- No other insider sold within 30 days.
- 847 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Blair Rainer sold about $2.5M of DHR on Aug 21, 2026; 847 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 31, 2024.
- The trade is 505.4% of the 7,755 shares held after it.
- No other insider sold within 30 days.
- 847 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Blair Rainer sold about $8.6M of DHR on Aug 21, 2026; 847 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 31, 2024.
- No other insider sold within 30 days.
- 847 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Blair Rainer sold about $1.7M of DHR on Aug 21, 2026; 847 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 7, 2025.
- The trade is 1.1% of the 124,093 shares held after it.
- No other insider sold within 30 days.
- 847 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SPOON ALAN G sold about $237.2K of DHR on May 1, 2026; 847 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 25.9% of the 5,099 shares held after it.
- No other insider sold within 30 days.
- 847 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Milosevich Gregory M sold about $274.6K of DHR on Feb 19, 2026; 847 funds added in the latest 13F quarter.126 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$13.0M over 180 days
-$12.7M over 90 days
below 81% of Industrials
Congress
no House purchase disclosed in the last 12 months
Funds
847 funds bought in last quarter
more than 95% of Industrials
Revenue
+2.9% year over year
below 60% of Industrials
Margin
14.7% net margin
more than 86% of Industrials
Buybacks
$894.0M repurchased, FY to 2026-09-25
more than 94% of Industrials
Short interest
1.3% of the float short (float per yahoo 2026-10-27) · 1.9 days to cover · settled 2026-10-15
below 77% of Industrials
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DHR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DHR: institutional holders (13F)
13F holdings, latest reported quarter
55,084,630 sh
$10.5B
41,377,076 sh
$7.9B
29,540,895 sh
$5.6B
28,456,019 sh
$5.4B
16,316,834 sh
$3.1B
Congress trades in DHR
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-02 · disclosed 23 days later
$1,001 - $15,000
Sold 2026-08-31 · disclosed 25 days later
$15,001 - $50,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-11-13 · disclosed 28 days later
$1,001 - $15,000
Bought 2025-10-07 · disclosed 38 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DHR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Rainer M. Blair
Filed 2026-08-21
$12.7M
SCHWIETERS JOHN T
Filed 2026-07-14
$658.3K
DHR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Medical Technology and Devices Portfolio
$449.4M position · as of 2026-05-31
15.1%
Eaton Vance Atlanta Capital Focused Growth Fund
$41.6M position · as of 2026-06-30
8.9%
Weitz Large Cap Equity Fund
$51.4M position · as of 2026-06-30
8.2%
Select Health Care Portfolio
$398.2M position · as of 2026-05-31
6.9%
Fidelity Advisor Health Care Fund
$210.6M position · as of 2026-07-31
6.8%
VIP Health Care Portfolio
$74.3M position · as of 2026-06-30
6.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
OTA - PANDEMIC PREPAREDNESS AND RESPONSE: ESTABLISHING A PLATFORM FOR DIAGNOSIS AND SURVEILLANCE OF · 2021-07-23
$80.2M
Department Of Veterans Affairs
MOLECULAR DIAGNOSTIC TESTS FOR SARS-COV-2 · 2024-03-20
$9.3M
Department Of Veterans Affairs
COST PER TEST · 2022-10-01
$4.9M
Department Of Veterans Affairs
REAGENTS · 2023-08-01
$4.1M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Rainer Blair
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$23.8M
$17.3M
$9.2M
+19%
+48%
2024
$22.1M
$7.5M
$6.7M
+19%
+29%
2023
$20.9M
$5.2M
$7.1M
+19%
+26%
2022
$20.2M
$190.3K
$6.6M
+20%
+24%
2021
$17.2M
$59.5M
$6.2M
+49%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $13.0M sold by insiders over 180 days, 847 funds added last quarter, $12.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
DHR financials
Revenue growth
+2.9%
XBRL, annual
Net margin
14.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$25.6B
four quarters, 2025-09-27 to 2026-09-25
Revenue, TTM DHR
| FY Dec 2025 | $24.6B |
| FY Dec 2024 | $23.9B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $29.5B |
| Sep 2026 | $6.6B |
| Jun 2026 | $6.3B |
| Mar 2026 | $6.0B |
| Dec 2025 | $6.8B |
| Sep 2025 | $6.1B |
| Jun 2025 | $5.9B |
| Mar 2025 | $5.7B |
| Dec 2024 | $6.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+16.9%
net income over revenue, 2025-09-27 to 2026-09-25
Net margin, TTM DHR
| FY Dec 2025 | +14.7% |
| FY Dec 2024 | +16.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +21.8% |
| Sep 2026 | +18.8% |
| Jun 2026 | +13.9% |
| Mar 2026 | +17.3% |
| Dec 2025 | +17.5% |
| Sep 2025 | +15.0% |
| Jun 2025 | +9.3% |
| Mar 2025 | +16.6% |
| Dec 2024 | +16.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$5.7B
operating cash flow minus capex, 2025-09-27 to 2026-09-25
Free cash flow, TTM DHR
| FY Dec 2025 | $5.3B |
| FY Dec 2024 | $5.3B |
| FY Dec 2023 | $5.8B |
| FY Dec 2022 | $7.4B |
| FY Dec 2021 | $7.1B |
| Sep 2026 | $1.6B |
| Jun 2026 | $1.3B |
| Mar 2026 | $1.1B |
| Dec 2025 | $1.7B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.1B |
| Mar 2025 | $1.1B |
| Dec 2024 | $1.5B |
At each fiscal year end
Single quarter
Debt to equity
0.49x
long-term 2026-09-25 plus current 2026-09-25; equity 2026-09-25
Debt to equity DHR
| FY Dec 2025 | 0.35x |
| FY Dec 2024 | 0.32x |
| FY Dec 2023 | 0.34x |
| FY Dec 2022 | 0.39x |
| FY Dec 2021 | 0.49x |
| Sep 2026 | 0.49x |
| Jun 2026 | 0.51x |
| Mar 2026 | 0.35x |
| Dec 2025 | 0.35x |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.33x |
| Mar 2025 | 0.32x |
| Dec 2024 | 0.32x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.26x
TTM operating cash flow over long-term 2026-09-25 plus current 2026-09-25
Cash flow to debt DHR
| FY Dec 2025 | 0.35x |
| FY Dec 2024 | 0.42x |
| FY Dec 2023 | 0.39x |
| FY Dec 2022 | 0.43x |
| FY Dec 2021 | 0.38x |
| Sep 2026 | 0.26x |
| Jun 2026 | 0.25x |
| Mar 2026 | 0.35x |
| Dec 2025 | 0.35x |
| Sep 2025 | 0.37x |
| Jun 2025 | 0.36x |
| Mar 2025 | 0.38x |
| Dec 2024 | 0.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+8.3%
TTM net income over average of 2025-09-26 and 2026-09-25
Return on equity DHR
| FY Dec 2025 | +7.1% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +15.1% |
| FY Dec 2021 | +15.1% |
| Sep 2026 | +8.3% |
| Jun 2026 | +7.6% |
| Mar 2026 | +7.1% |
| Dec 2025 | +7.1% |
| Sep 2025 | +6.8% |
| Jun 2025 | +6.7% |
| Mar 2025 | +7.2% |
| Dec 2024 | +7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.0%
TTM net income over average of 2025-09-26 and 2026-09-25
Return on assets DHR
| FY Dec 2025 | +4.5% |
| FY Dec 2024 | +4.8% |
| FY Dec 2023 | +5.6% |
| FY Dec 2022 | +8.6% |
| FY Dec 2021 | +8.1% |
| Sep 2026 | +5.0% |
| Jun 2026 | +4.6% |
| Mar 2026 | +4.5% |
| Dec 2025 | +4.5% |
| Sep 2025 | +4.4% |
| Jun 2025 | +4.3% |
| Mar 2025 | +4.6% |
| Dec 2024 | +4.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+6.7%
operating income after a 11.0% effective tax rate, over long-term 2026-09-25 plus current 2026-09-25 plus average of 2025-09-26 and 2026-09-25 minus cash
Return on invested capital DHR
| FY Dec 2025 | +6.7% |
| FY Dec 2024 | +7.1% |
| FY Dec 2023 | +7.2% |
| FY Dec 2022 | +11.6% |
| FY Dec 2021 | +9.8% |
| Sep 2026 | +6.7% |
| Jun 2026 | +6.2% |
| Mar 2026 | +6.7% |
| Dec 2025 | +6.7% |
| Sep 2025 | +6.7% |
| Jun 2025 | +6.3% |
| Mar 2025 | +6.9% |
| Dec 2024 | +7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+6.6%
operating income (EBIT proxy) over average of 2025-09-26 and 2026-09-25 minus current liabilities
Return on capital employed DHR
| FY Dec 2025 | +6.4% |
| FY Dec 2024 | +6.6% |
| FY Dec 2023 | +6.8% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +8.9% |
| Sep 2026 | +6.6% |
| Jun 2026 | +6.4% |
| Mar 2026 | +6.4% |
| Dec 2025 | +6.4% |
| Sep 2025 | +6.3% |
| Jun 2025 | +6.0% |
| Mar 2025 | +6.5% |
| Dec 2024 | +6.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
38.13x
close 2026-10-26 over four quarters of diluted EPS, 2025-09-27 to 2026-09-25
P/E, trailing DHR
| FY Dec 2025 | 45.42x |
| FY Dec 2024 | 43.48x |
| FY Dec 2023 | 36.20x |
| FY Dec 2022 | 24.38x |
| FY Dec 2021 | 33.84x |
| Sep 2026 | 36.74x |
| Jun 2026 | 34.85x |
| Mar 2026 | 35.11x |
| Dec 2025 | 45.42x |
| Sep 2025 | 38.11x |
| Jun 2025 | 42.30x |
| Mar 2025 | 39.97x |
| Dec 2024 | 43.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$184.7B
market value at close 2026-10-26 on 2026-10-15 shares, plus long-term 2026-09-25 plus current 2026-09-25, minus cash 2020-10-02
Enterprise value DHR
| FY Dec 2025 | $174.4B |
| FY Dec 2024 | $176.1B |
| FY Dec 2023 | $183.7B |
| FY Dec 2022 | $185.3B |
| FY Dec 2021 | $224.9B |
| Sep 2026 | $178.6B |
| Jun 2026 | $159.7B |
| Mar 2026 | $141.2B |
| Dec 2025 | $174.4B |
| Sep 2025 | $143.5B |
| Jun 2025 | $153.9B |
| Mar 2025 | $157.9B |
| Dec 2024 | $176.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield DHR
| FY Dec 2025 | +3.3% |
| FY Dec 2024 | +3.2% |
| FY Dec 2023 | +3.4% |
| FY Dec 2022 | +4.3% |
| FY Dec 2021 | +3.4% |
| Sep 2026 | +3.6% |
| Jun 2026 | +3.9% |
| Mar 2026 | +4.1% |
| Dec 2025 | +3.3% |
| Sep 2025 | +3.8% |
| Jun 2025 | +3.4% |
| Mar 2025 | +3.3% |
| Dec 2024 | +3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.47x
P/E over trailing EPS growth of 26%: four quarters to 2026-09-25 against the four to 2025-09-26
PEG, trailing DHR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 2.04x |
| FY Dec 2021 | 0.44x |
| Sep 2026 | 1.41x |
| Jun 2026 | 1.76x |
| Mar 2026 | 90.41x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $24.6B | $23.9B | $23.9B | $31.5B |
| Gross profit | $14.5B | $14.2B | $14.0B | $16.2B |
| Operating income | $4.7B | $4.9B | $5.2B | $7.5B |
| Net income | $3.6B | $3.9B | $4.8B | $7.2B |
| EPS (diluted) | 5.05 | 5.29 | 6.38 | 9.66 |
| Operating cash flow | $6.4B | $6.7B | $7.2B | $8.5B |
| Long-term debt | $18.4B | $15.5B | $16.7B | $19.1B |
| Buybacks | $3.1B | $6.0B | $0 | $0 |
| Dividends paid | $878.0M | $768.0M | $821.0M | $818.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
DHR Stock Sonar score 6/7 axes
Find similar shapesCompareDHR ranks highest on growth (63rd percentile) and institutional and government (60th), and lowest on insider conviction (9th), among Industrials peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DHR filings, in plain words
Are Danaher insiders buying or selling DHR?
In the 180 days to 2026-10-28, Danaher insiders were net sellers, a net $13.0M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded DHR?
Yes. In the year to 2026-10-28, 0 House members disclosed buying DHR and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-02.
Are there planned insider sales of DHR?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $12.7M of stock; the latest, by Rainer M. Blair, was filed 2026-08-21.
Read the full summary
In the 180 days to 2026-10-28, Danaher insiders were net sellers of DHR, a net $13.0M across purchases and sales reported on Form 4 by 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 0 members of Congress disclosed buying DHR and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-02. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $12.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
